Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Can-Fite Biopharma Ltd ADR (NY: CANF )

2.000 +0.030 (+1.52%)
Official Closing Price Updated: 8:00 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,679
Open 2.000
Bid (Size) 1.960 (5)
Ask (Size) 2.080 (3)
Prev. Close 1.970
Today's Range 1.940 - 2.035
52wk Range 1.810 - 4.690
Shares Outstanding 515,746,293
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire

Performance

YTD
-3.38%
-3.38%
1 Month
-11.11%
-11.11%
3 Month
-22.48%
-22.48%
6 Month
-16.67%
-16.67%
1 Year
-7.41%
-7.41%

More News

Read More
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
From Can-Fite BioPharma Ltd.
Via Business Wire
Can Fite Biofarma: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
From Can-Fite BioPharma Ltd.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Can-Fite Reports 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.